• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Navidea Biopharmaceuticals opens new facility in Andover, Mass.

Navidea Biopharmaceuticals opens new facility in Andover, Mass.

June 11, 2012
CenterWatch Staff

Navidea Biopharmaceuticals, a Dublin, Ohio-based specialty biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, has opened its new business and commercialization facility in Andover, Mass.

Navidea’s new facility, located in the New England Business Center, will serve as the business development office and the commercialization center for the commercial launch of the company’s lead radiopharmaceutical product, Lymphoseek, anticipated later this year. Lymphoseek is a proprietary lymph node targeting agent intended for use in intraoperative lymphatic mapping (ILM) procedures conducted by oncology surgeons.

“In establishing our business development and commercialization center, Massachusetts provides an ideal environment to support our expanding business and portfolio —including world-class biopharmaceutical organizations and infrastructure, and access to leading academic, medical and industry centers,” said Mark Pykett, president and CEO of Navidea. “This is an important step of expanding our business reach, and we look forward to many years of benefiting from the region’s outstanding assets and being true partners to the state and our industry and academic neighbors.”

“We are pleased to welcome Navidea Biopharmaceuticals to Massachusetts as they work toward commercializing an important innovative technology with the potential to help oncology surgeons more effectively and accurately diagnose cancer,” said Bob Coughlin, president and CEO of MassBio. “We look forward to supporting Navidea in its ongoing endeavors in the development of important new pathways to diagnose critical diseases and forge collaborations with other leading companies and innovation centers in Massachusetts.”

Susan Houston, executive director of Massachusetts Alliance for Economic Development, added “Adding innovative companies like Navidea to Massachusetts is a critical part of ensuring the continued economic vitality of the state. With the tremendous connections our state provides to growing companies, I am confident Massachusetts and Navidea will both benefit from a strong and lasting partnership.”

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing